ACS CAN calls on the White House, Congress to prioritize tobacco control and cancer research

In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?

The National Cancer Registries Program, or NPCR, is a relatively small but highly impactful 33-year-old CDC program that gauges disparities in cancer and tracks progress against the disease. So, why was it left out of the Trump administration’s preliminary budget?

April 30, 2025

Vol.51 No.16

Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

April 25, 2025

Vol.51 No.16

By Richard M. Goldberg

Cancer Policy

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

Over the past week, as cancer control experts scoured through a confidential budget document called the “passback” budget, they haven’t been able to find any trace of a relatively small but highly impactful program that funds state cancer registries.

DOJ letters to peer-reviewed journals allege partisan bias in medical literature

At least two medical journals have received letters from the Trump administration accusing them of political bias.

April 25, 2025

Vol.51 No.16

By Claire Marie Porter

Conversation with The Cancer Letter

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.

March 21, 2025

Vol.51 No.11

By Claire Marie Porter and Jacquelyn Cobb

ACS CAN calls on the White House, Congress to prioritize tobacco control and cancer research

YOU MAY BE INTERESTED IN

In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?

Regulation must keep up with scientific advances

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

DOJ letters to peer-reviewed journals allege partisan bias in medical literature

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

Renew today!

Subscriber content

Never miss an issue!

Login